CD274 and plasma cell myeloma: In a mouse model of multiple myeloma, BMSCs are reported to inhibit T cells immune response by means of the PD-1/PD-L1 signaling pathway, thereby promoting the development of multiple myeloma, and markedly shortening mouse survival (24).